GlassScriptPhysician profile
Gary L Werntz
NPI 1952301285
$17,591.16
in general payments reported to CMS, 2019-2025
46 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,933 · 2020: $533 · 2021: $372 · 2022: $2,035 · 2023: $2,816 · 2024: $2,440 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,671 · Education: $46.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,671.28 |
| Education | $46.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,585.53 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,218.47 | 2019-2025 | Apretude, Rukobia, Cabenuva |
| Novo Nordisk INC | $986.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $873.95 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $784.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $664.71 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $516.78 | 2019-2025 | Gardasil 9, Capvaxive, Pifeltro |
| Takeda Pharmaceuticals U.S.A., INC. | $494.35 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $486.65 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $384.68 | 2019-2025 | |
| Emd Serono, INC. | $324.48 | 2019-2025 | Serostim |
| Amgen INC. | $287.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Biotech, INC. | $239.58 | 2019-2023 | Symtuza |
| Abbott Laboratories | $170.77 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Prodigy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.03 | 2019-2025 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Werntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.